Literature DB >> 5302328

Cholera vaccine field trials in east Pakistan. 1. Reaction and antigenicity studies.

A S Benenson, P R Joseph, R O Oseasohn.   

Abstract

Double-blind controlled cholera-vaccine trials were carried out in rural East Pakistan in 1963 and 1964. Pretrial studies indicated that a whole-cell cholera vaccine of high mouse protective potency, at a dose of 0.5 ml, produced an antibody response and reaction pattern consistent with use in such trials. A purified Ogawa antigen, given at a dose of 100 mug, elicited no adverse reactions and evoked both agglutinating and vibriocidal antibodies against both Inaba and Ogawa test suspensions.In the field, adverse reactions to the cholera vaccines occurred primarily among adults and were observed with both the whole-cell preparation and the purified Ogawa antigen. At the dose used in the field trials (0.4 ml), the reactions elicited by the whole-cell vaccine were acceptable to the population and no more marked than those following the locally prepared typhoid-paratyphoid vaccine. Delayed reactions to the whole-cell cholera vaccine were observed beginning 4 to 7 days after the vaccine was administered; the bulk of them (60%) did not interfere with work at any time; all resolved promptly; and none developed fluctuation or was associated with abscess formation.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5302328      PMCID: PMC2554479     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  9 in total

1.  FIELD TRIAL OF CHOLERA VACCINE IN RURAL EAST PAKISTAN. FIRST YEAR OF OBSERVATION.

Authors:  R O OSEASOHN; A S BENENSON; M FAHIMUDDIN
Journal:  Lancet       Date:  1965-02-27       Impact factor: 79.321

2.  LABORATORY ASSAYS OF CHOLERA VACCINE USED IN FIELD TRIAL IN EAST PAKISTAN, 1963.

Authors:  J C FEELEY; M PITTMAN
Journal:  Lancet       Date:  1965-02-27       Impact factor: 79.321

3.  Serologic diagnosis of cholera.

Authors:  K GOODNER; H L SMITH; H STEMPEN
Journal:  J Albert Einstein Med Cent (Phila)       Date:  1960-04

4.  Antibody Response and Systemic Reactions after Inoculation of a New Type of T.A.B.C. Vaccine.

Authors:  A Felix; S G Rainsford; E J Stokes
Journal:  Br Med J       Date:  1941-03-22

5.  Protective antigens from El Tor vibrios. 1. The preparation and properties of a purified protective antigen from an El Tor vibrio (Ogawa subtype).

Authors:  Y Watanabe; W F Verwey
Journal:  Bull World Health Organ       Date:  1965       Impact factor: 9.408

6.  Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field.

Authors:  A S Benenson; W H Mosley; M Fahimuddin; R O Oseasohn
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

7.  Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; W H Mosley
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

8.  Serological studies in cholera. I. Vibrio agglutinin response of cholera patients determined by a microtechnique.

Authors:  A S Benenson; A Saad; M Paul
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

9.  Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta.

Authors:  A Das Gupta; R Sinha; D L Shrivastava; S P De; B L Taneja; M S Rao; A H Abou-Gareeb
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

  9 in total
  10 in total

Review 1.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

2.  A serological survey for cholera antibodies in rural east Pakistan. 2. A comparison of antibody titres in the innunized and control populationd of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate.

Authors:  W H Mosley; A S Benenson; R Barui
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

3.  Comparative study of reactions and serological response to cholera vaccines in a controlled field trial conducted in the USSR.

Authors:  P N Burgasov; A A Sumarokov; V L Lelikov; L M Marcuk; V G Fedenev; M N Dzaparidze; L T Karaeva; I I Derteva
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

Review 4.  Vibrio cholerae: lessons for mucosal vaccine design.

Authors:  Anne L Bishop; Andrew Camilli
Journal:  Expert Rev Vaccines       Date:  2011-01       Impact factor: 5.217

5.  Immunochemical studies on lipopolysaccharide from agglutinable and non-agglutinable vibrios.

Authors:  B Guhathakurta; G C Dutta
Journal:  Appl Microbiol       Date:  1974-04

6.  Experimental Cholera in Chinchillas: the Immune Response in Serum and Intestinal Secretions to Vibrio cholerae and Cholera Toxin.

Authors:  U Blachman; S R Graboff; G E Haag; E Gottfeld; M J Pickett
Journal:  Infect Immun       Date:  1974-11       Impact factor: 3.441

7.  Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field.

Authors:  A S Benenson; W H Mosley; M Fahimuddin; R O Oseasohn
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

Review 8.  Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected).

Authors:  Patricia M Graves; Jonathan J Deeks; Vittorio Demicheli; Tom Jefferson
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

9.  Production of putative enhanced oral cholera vaccine strains that express toxin-coregulated pilus.

Authors:  Caitlyn A Hauke; Ronald K Taylor
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

10.  Scalable production and immunogenicity of a cholera conjugate vaccine.

Authors:  Suhi Jeon; Meagan Kelly; Jeesun Yun; Byungman Lee; Minchul Park; Yoonhee Whang; Chankyu Lee; Yuan-Di Halvorsen; Smriti Verma; Richelle C Charles; Jason B Harris; Stephen B Calderwood; Daniel T Leung; Taufiqur R Bhuiyan; Firdausi Qadri; Mohammad Kamruzzaman; Somyoung Cho; Willie F Vann; Peng Xu; Pavol Kováč; Ravi Ganapathy; Julia Lynch; Edward T Ryan
Journal:  Vaccine       Date:  2021-10-27       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.